People

Cynthia T. Mazareas

Partner

Mazareas_Cynthia

Cynthia Mazareas is a leading corporate attorney and trusted business advisor to companies in the life sciences, medical device and biopharmaceutical industries. She has more than 25 years of experience providing ongoing, strategic business counsel to boards, management teams and in-house counsel, representing both high-growth private and public companies in day-to-day corporate matters and helping these companies navigate through complex business transactions. She is a member of the firm's Life Sciences Group and Public Company Counseling Group.

Whatever type of client or matter might land on her desk, Ms. Mazareas takes great pride in her work. She has a deep appreciation for the life sciences field, as her clients are developing innovations to improve the lives of those affected by various medical conditions. Therefore, she considers herself a business partner to her clients and offers practical and solutions-oriented advice based on her deep knowledge of the legal issues unique to the industry.

In addition to advising clients on a wide range of corporate matters, Ms. Mazareas has significant experience counseling public and private companies in venture capital and public securities offerings including IPOs, PIPEs, registered direct and Rule 144A convertible debt offerings, as well as mergers and acquisitions, strategic alliances, matters of SEC, NASDAQ and Sarbanes-Oxley compliance and corporate governance.

Honors & Awards

Publications & News

View

January 2, 2018

WilmerHale Announces 2018 Partner Elevations

We are pleased to announce the elevation of our new partners.

December 29, 2017

WilmerHale Represents Arsanis in Closing of Initial Public Offering

Arsanis, Inc., a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, announced the closing of its initial public offering of 4,600,000 shares of its common stock at a public offering price of $10 per share, including 600,000 additional shares of common stock issued upon the exercise in full by the underwriters of their over-allotment option.

November 17, 2017

WilmerHale Reps Achillion Pharmaceuticals in Pricing of Secondary Offering of Common Stock

Achillion Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 18,367,346 shares of its common stock by existing stockholder Johnson & Johnson Innovation-JJDC, Inc., which shares constitute all of JJDC's equity position in Achillion, at a public offering price of $2.75 per share.

September 19, 2017

LMG Life Sciences Names WilmerHale Life Cycle Firm of the Year and Lisa Pirozzolo General Patent Litigator of the Year

Lawyers from across the United States and Canada gathered on September 13 at the Essex House in New York to celebrate the annual LMG Life Sciences Awards, recognizing the 2017 top firms and legal professionals in the life science industry.

July 20, 2017

LMG Life Sciences Recognizes WilmerHale in 13 Categories on 2017 Award Shortlist

In its annual recognition of the top law firms, lawyers and in-house counsel in the life sciences industry, LMG Life Sciences named WilmerHale to its 2017 award shortlist in 13 categories.

May 11, 2017

Agios Pharmaceuticals Announces Closing of Over-Allotment Option in Public Offering

Agios Pharmaceuticals, Inc. announced that it has issued an additional 757,575 shares of common stock at the public offering price of $49.50 per share, for total gross proceeds of approximately $37 million.

April 26, 2017

WilmerHale Counsels Syros Pharmaceuticals in $35M Private Placement

Syros Pharmaceuticals, a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, announced that it has entered into a stock purchase agreement with several institutional accredited investors.

April 4, 2017

AVEO Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

WilmerHale client AVEO Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering of 34,500,000 shares of common stock.

September 22, 2016

WilmerHale Advises Agios Pharmaceuticals in $173M Public Offering and Full Exercise of Option to Purchase Additional Shares

The WilmerHale team was led by Partner Steven Singer and included Special Counsel Cynthia Mazareas, Senior Associate Mhairi Immermann and Associate Brett Bromann.

July 5, 2016

WilmerHale Advises Syros Pharma in Initial Public Offering

WilmerHale advised Syros Pharmaceuticals, Inc., a life sciences company, in its initial public offering.

Recent Highlights

  • Representation of Arsanis in its initial public offering
  • Representation of Agios Pharmaceuticals in several follow-on offerings as well as its initial public offering and side-by-side private placement with Celgene Corporation
  • Representation of Syros Pharmaceuticals in its initial public offering, follow-on public offering and side-by-side private placement with Incyte Corporation and PIPE
  • Representation of Achillion Pharmaceuticals in its strategic equity investment by Johnson & Johnson Innovation-JJDC, Inc., and its secondary sale by Johnson & Johnson Innovation-JJDC, Inc.
  • Representation of Achillion Pharmaceuticals in its registered direct offering with a privately owned hedge fund sponsor
  • Representation of Infinity Pharmaceuticals in its reverse merger/going public transaction, its strategic equity transactions with Purdue Pharma and Purdue Pharma's subsequent secondary underwritten public offerings
  • Representation of numerous publicly traded life science companies in underwritten follow-on offerings, including Agios Pharmaceuticals, Achillion Pharmaceuticals, AVEO Pharmaceuticals, Curis, and Infinity Pharmaceuticals
  • Representation of several public companies in the establishment of "at-the-market" sales arrangements
  • Representation of several publicly traded life science and medical device companies in PIPE, registered direct, Rule 144A convertible debt and strategic equity transactions
  • Representation of numerous privately held life science companies in early-stage, bridge and mezzanine venture capital transactions, including BlinkBio, KEW Group and Translate Bio

Professional Activities

Ms. Mazareas is an author and speaker on corporate transactions, governance and other matters relating to life sciences and biotechnology companies.

Ms. Mazareas is a member of the Massachusetts Biotechnology Council, the Massachusetts Bar Association and the Boston Bar Association. She is also a member of the firm's Women's Leadership Initiative.

Community Involvement

Ms. Mazareas serves on the Board of Trustees of Shore Country Day School. She is also a former member of the Board of Directors for Prize4Life, Inc.

Practices

Skip Navigation Links.

Education

JD, Georgetown University Law Center, 1993

BS, Boston University, 1985

Bar Admissions

Massachusetts

Skip Navigation Links.